Immutep Ltd - IMMP Future Profit

Corporate company logo of Immutep Limited ADR (IMMP)

The cancer immunotherapy market is currently expanding rapidly driven by innovative LAG-3 drugs. Immutep Limited (IMMP) shows an upward trend in expected net profit, while reflects the latest metric level. This growth is based on the global expansion of the pipeline through partnerships. Model flexibility is maintained via the full outsourcing of production and clinical trials, which eliminates unnecessary capital expenditures.

IMMP - Immutep Limited Future Profit over the range 07/04/2022 - 11/15/2026

Analytical breakdowns for Immutep Limited

- price and consensus price forecast:
Price Chart Immutep|IMMP - Fair Value Consensus
- issuer market value details:
Market Valuation Immutep Limited ADR|IMMP - Value Adjusted for Debt and Cash
- book capitalization information:
Accounting Value per Share Immutep|IMMP - Company Net Assets|Market Value to Book Value Ratio immutep.com|IMMP - Company Assets
- company total debt and liquidity indicators:
Debt to Equity Immutep Limited|IMMP - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Immutep Ltd|IMMP - Company Cumulative Debt|Debt to Book Capitalization Ratio Immutep Corp|IMMP - Company Long-Term Indebtedness|Company Short-Term Debts Immutep|Quick Liquidity immutep.com
- earnings and market ratios statistics:
IMMP - Net Income|Expected Profit Immutep Limited|IMMP - Price to Earnings Ratio|Projected Price to Earnings Immutep Ltd|IMMP - PEG Multiple|Enterprise Value to EBITDA Ratio Immutep|IMMP - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Immutep|IMMP - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months immutep.com|IMMP - Earnings per share trend in current year|Expected earnings per share growth for next year Immutep Limited
- sales volume and revenue indicators:
IMMP - Company Sales Revenue|Company Projected Revenue Immutep|IMMP - Price-to-Revenue Ratio|Forward P/S Multiple Immutep Corp
Fundamental company analysis:IMMP, Immutep Limited ADR
Core merchandise of Immutep Ltd

This metric assesses expected net profit by measuring the business model's resilience to market volatility through an analysis of deviations between projected values and historical averages. By analyzing the forecast for financial returns, an investor can discern the sensitivity of calculations to reporting, which is critical for Immutep Limited (IMMP) during the scaling of its LAG-3 oncology portfolio and the implementation of partnership programs with global biopharmaceutical behemoths.

Competing companies

Expected Profit Merus|ANIX: Expected Net Income|Future Profit ATOS (Atossa)|CNTX (Context Tx) - Expected Net Income|Mersana Therapeutics - Future Profit|BCTX - Future Profit|EPIX - Expected Profit|QT Imaging (QTI) - Future Profit